These results position tirzepatide as a favored choice for patients requiring seriously glycemic administration without compromising weight administration goals
Safety in TRIUMPH-1 The safety profile was consistent with incretin-class therapies: Most common AEs (12 mg dose): - Nausea: 42.4% - Diarrhea: 32.0% - Constipation: 26.1% - Vomiting: 25.3% Dysesthesia (a sensory disturbance tingling, numbness) and urinary tract infections were reported in approximately 10% of patients on the highest doses, but were generally mild to moderate and mostly resolved during treatment
M.BakrisG.Bosch-TrabergH.GislumM.GoughS
When injected, it binds to GLP-1 receptors throughout the body, including in the brain, pancreas, and gut
Toxic metabolites derived from CYP2E1 recruit leukocytes and hepatic stellate cells (HSCs), exacerbating the hepatic inflammatory response and fibrotic processes (Zhang et al
The possible reasons for this might be differences in sociodemographic, lifestyle, study design, ART combination, and ART exposure status